Nu.Q® Vet Cancer Test Launched in Collaboration between Volition and Fujifilm

March 20, 2024, 1:30 p.m. Health

Nu.Q® Vet Cancer Test Launched in Collaboration between Volition and Fujifilm

In a groundbreaking development in the field of veterinary diagnostics, Volition, a leading multi-national life sciences company, has joined hands with Fujifilm, an innovative technology company, to launch the Nu.Q® Vet Cancer Test. This partnership brings together the expertise of both companies to provide a cutting-edge diagnostic tool that aims to revolutionize the way cancer in pets is diagnosed and treated.

The Nu.Q® Vet Cancer Test is a non-invasive blood test that detects biomarkers associated with various types of cancer in dogs and cats. By analyzing these specific biomarkers, veterinarians can identify the presence of cancer at an early stage, allowing for prompt intervention and treatment. This groundbreaking test represents a significant advancement in the field of veterinary oncology, offering pet owners the opportunity to detect and address cancer in their beloved companions with greater accuracy and efficiency.

Volition is renowned for its expertise in developing innovative blood-based diagnostic tests for human health, and the collaboration with Fujifilm highlights the company's commitment to expanding its diagnostic capabilities into the veterinary space. By leveraging Fujifilm's cutting-edge technology and imaging expertise, Volition aims to enhance the accuracy and sensitivity of the Nu.Q® Vet Cancer Test, providing veterinarians with a powerful tool to improve the outcomes of cancer treatment in pets.

Fujifilm, a global leader in imaging and diagnostic technologies, brings its expertise in developing advanced imaging solutions to the partnership with Volition. The company's state-of-the-art imaging technologies will be utilized to enhance the analysis and interpretation of the biomarkers detected in the Nu.Q® Vet Cancer Test, enabling veterinarians to make more informed diagnostic and treatment decisions for their patients.

The Nu.Q® Vet Cancer Test is based on Volition's proprietary Nu.Q® technology platform, which has been extensively validated in human clinical studies. This proven technology forms the foundation of the new veterinary cancer test, demonstrating the reliability and effectiveness of the diagnostic tool in detecting cancer biomarkers in blood samples from pets.

With cancer being a leading cause of death in dogs and cats, early detection and treatment are crucial in improving the prognosis and quality of life for affected animals. The Nu.Q® Vet Cancer Test offers a non-invasive and accessible solution for veterinarians and pet owners to detect cancer at an early stage, facilitating timely intervention and personalized treatment plans tailored to the individual needs of each pet.

The collaboration between Volition and Fujifilm represents a significant milestone in the advancement of veterinary diagnostics, bringing together two industry leaders to address a critical unmet need in the field of veterinary oncology. By combining their expertise and innovative technologies, the two companies have developed a powerful diagnostic tool that has the potential to transform the way cancer is diagnosed and managed in pets, offering new hope for improved outcomes and quality of life for companion animals worldwide.

In conclusion, the launch of the Nu.Q® Vet Cancer Test marks a significant milestone in the field of veterinary oncology, showcasing the power of collaboration between industry leaders to drive innovation and advance diagnostic capabilities for the benefit of pets and their owners. This groundbreaking test represents a major step forward in the detection and treatment of cancer in dogs and cats, offering veterinarians a powerful tool to improve outcomes and provide personalized care for their patients. With the combined expertise of Volition and Fujifilm, the Nu.Q® Vet Cancer Test holds great promise in revolutionizing the way cancer is diagnosed and managed in the veterinary setting, heralding a new era of precision medicine for companion animals.